These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 20876137)

  • 1. Elicitation of structure-specific antibodies by epitope scaffolds.
    Ofek G; Guenaga FJ; Schief WR; Skinner J; Baker D; Wyatt R; Kwong PD
    Proc Natl Acad Sci U S A; 2010 Oct; 107(42):17880-7. PubMed ID: 20876137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant.
    Guenaga J; Dosenovic P; Ofek G; Baker D; Schief WR; Kwong PD; Karlsson Hedestam GB; Wyatt RT
    PLoS One; 2011 Jan; 6(1):e16074. PubMed ID: 21297864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-affinity relationships in the gp41 ELDKWA epitope for the HIV-1 neutralizing monoclonal antibody 2F5: effects of side-chain and backbone modifications and conformational constraints.
    Tian Y; Ramesh CV; Ma X; Naqvi S; Patel T; Cenizal T; Tiscione M; Diaz K; Crea T; Arnold E; Arnold GF; Taylor JW
    J Pept Res; 2002 Jun; 59(6):264-76. PubMed ID: 12010517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems.
    Veiga AS; Pattenden LK; Fletcher JM; Castanho MA; Aguilar MI
    Chembiochem; 2009 Apr; 10(6):1032-44. PubMed ID: 19283693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6.
    Ofek G; Zirkle B; Yang Y; Zhu Z; McKee K; Zhang B; Chuang GY; Georgiev IS; O'Dell S; Doria-Rose N; Mascola JR; Dimitrov DS; Kwong PD
    J Virol; 2014 Mar; 88(5):2426-41. PubMed ID: 24335316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.
    Ofek G; Tang M; Sambor A; Katinger H; Mascola JR; Wyatt R; Kwong PD
    J Virol; 2004 Oct; 78(19):10724-37. PubMed ID: 15367639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications.
    Bryson S; Julien JP; Hynes RC; Pai EF
    J Virol; 2009 Nov; 83(22):11862-75. PubMed ID: 19740978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies.
    Li D; Liu J; Zhang L; Xu T; Chen J; Wang L; Zhao Q
    Virol Sin; 2015 Dec; 30(6):449-56. PubMed ID: 26715302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site.
    Julien JP; Bryson S; Nieva JL; Pai EF
    J Mol Biol; 2008 Dec; 384(2):377-92. PubMed ID: 18824005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico vaccine design based on molecular simulations of rhinovirus chimeras presenting HIV-1 gp41 epitopes.
    Lapelosa M; Gallicchio E; Arnold GF; Arnold E; Levy RM
    J Mol Biol; 2009 Jan; 385(2):675-91. PubMed ID: 19026659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody.
    Tudor D; Yu H; Maupetit J; Drillet AS; Bouceba T; Schwartz-Cornil I; Lopalco L; Tuffery P; Bomsel M
    Proc Natl Acad Sci U S A; 2012 Jul; 109(31):12680-5. PubMed ID: 22723360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress towards the development of a HIV-1 gp41-directed vaccine.
    McGaughey GB; Barbato G; Bianchi E; Freidinger RM; Garsky VM; Hurni WM; Joyce JG; Liang X; Miller MD; Pessi A; Shiver JW; Bogusky MJ
    Curr HIV Res; 2004 Apr; 2(2):193-204. PubMed ID: 15078183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb.
    McGaughey GB; Citron M; Danzeisen RC; Freidinger RM; Garsky VM; Hurni WM; Joyce JG; Liang X; Miller M; Shiver J; Bogusky MJ
    Biochemistry; 2003 Mar; 42(11):3214-23. PubMed ID: 12641452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Membrane association and epitope recognition by HIV-1 neutralizing anti-gp41 2F5 and 4E10 antibodies.
    Sánchez-Martínez S; Lorizate M; Katinger H; Kunert R; Nieva JL
    AIDS Res Hum Retroviruses; 2006 Oct; 22(10):998-1006. PubMed ID: 17067270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal structure of the complex between the F(ab)' fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6.
    Bryson S; Julien JP; Isenman DE; Kunert R; Katinger H; Pai EF
    J Mol Biol; 2008 Oct; 382(4):910-9. PubMed ID: 18692506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.
    Parker CE; Deterding LJ; Hager-Braun C; Binley JM; Schülke N; Katinger H; Moore JP; Tomer KB
    J Virol; 2001 Nov; 75(22):10906-11. PubMed ID: 11602730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational design of protein antigens that interact with the CDR H3 loop of HIV broadly neutralizing antibody 2F5.
    Azoitei ML; Ban YA; Kalyuzhny O; Guenaga J; Schroeter A; Porter J; Wyatt R; Schief WR
    Proteins; 2014 Oct; 82(10):2770-82. PubMed ID: 25043744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.
    Zwick MB; Jensen R; Church S; Wang M; Stiegler G; Kunert R; Katinger H; Burton DR
    J Virol; 2005 Jan; 79(2):1252-61. PubMed ID: 15613352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes.
    Alam SM; McAdams M; Boren D; Rak M; Scearce RM; Gao F; Camacho ZT; Gewirth D; Kelsoe G; Chen P; Haynes BF
    J Immunol; 2007 Apr; 178(7):4424-35. PubMed ID: 17372000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5.
    Zwick MB; Komori HK; Stanfield RL; Church S; Wang M; Parren PW; Kunert R; Katinger H; Wilson IA; Burton DR
    J Virol; 2004 Mar; 78(6):3155-61. PubMed ID: 14990736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.